Camurus Navigation ABOUT CAMURUS CEO statement Management team Board of directors Career Code of conduct PRODUCTS CAM2038 Opioid Dependence CAM2029 Growth Hormone Disorders CAM2038 Chronic Pain CAM2032 Prostate Cancer episil® Oral Liquid TECHNOLOGIES FluidCrystal® injection depot FluidCrystal® topical bioadhesive FluidCrystal® nanoparticles INVESTORS Share & Shareholders Presentations Annual general meeting Subscription Financial reports Press releases Financial calendar Corporate governance MEDIA CONTACT ABOUT CAMURUS CEO statement Management team Board of directors Career Code of conduct PRODUCTS CAM2038 Opioid Dependence CAM2029 Growth Hormone Disorders CAM2038 Chronic Pain CAM2032 Prostate Cancer episil® Oral Liquid TECHNOLOGIES FluidCrystal® injection depot FluidCrystal® topical bioadhesive FluidCrystal® nanoparticles INVESTORS Share & Shareholders Presentations Annual general meeting Subscription Financial reports Press releases Financial calendar Corporate governance MEDIA CONTACT THE CAMURUS SHARE 119.75 SEK 0% XSTO 2017-05-05 17:29 THE CAMURUS SHARE 119.75 SEK 0% XSTO 2017-05-05 17:29 ABOUT CAMURUS Delivering better treatments Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. More about Camurus ABOUT CAMURUS Delivering better treatments Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. More about Camurus PRESS RELEASES 2017-05-03 Resolutions at the annual general... 2017-05-03 Interim Report January-March 2017 2017-05-02 Camurus and Braeburn... 2017-03-31 Camurus appoints VP Corporate... Archive FINANCIAL CALENDAR 2017-07-13 Interim report January-June 2017 2017-10-26 Interim Report January-September... 2018-02-15 Full Year Report 2017 2018-03-22 Annual Report 2017 Archive EVENTS 2017-06-17 CPDD Annual Scientific Meeting 2017-06-19 BIO 2017 2017-10-24 CPhI Worldwide 2017-11-06 BIO-Europe Archive “New top-line Phase 3 results support the longterm safety and efficacy of CAM2038 in patients with opioid dependence„ Fredrik Tiberg, CEO DEVELOPMENT PIPELINE Transforming treatments for patients with serious and chronic diseases Camurus’ clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. See our products DEVELOPMENT PIPELINE Transforming treatments for patients with serious and chronic diseases Camurus’ clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development. Our innovative product candidates are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. See our products CAM2038 OPIOID DEPENDENCE CAM2029 GROWTH HORMONE DISORDERS CAM2038 CHRONIC PAIN CAM2032 PROSTATE CANCER EPISIL® ORAL LIQUID INVESTOR RELATIONS Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us. Investor relations INVESTOR RELATIONS Welcome to the investor relations section. Our ambition is to regularly update shareholders and others on the capital market about Camurus’ status and performance. This is done via press releases, quarterly reports, and presentations at different life science and investment conferences. If you have questions, please don’t hesitate to contact us. Investor relations CAM2038 has the potential to become a game-changer in opioid dependence treatment Fredrik Tiberg CEO Statement CAM2038 has the potential to become a game-changer in opioid dependence treatment Fredrik Tiberg CEO Statement TECHNOLOGIES FluidCrystal® – smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. Technologies TECHNOLOGIES FluidCrystal® – smart and versatile drug delivery Camurus’ FluidCrystal® technologies are all based on special combinations of endogenous polar lipids that spontaneously form liquid crystal nanostructures in aqueous environments; at tissue surfaces or in the body. By combining these with active ingredients with proven efficacy and safety profiles, new patented medicines are developed at significantly lower cost and risk, compared with the development of new medicines. Technologies FluidCrystal® INJECTION DEPOT FluidCrystal® TOPICAL BIOADHESIVE FluidCrystal® NANOPARTICLES Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Sölvegatan 41 A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations ir@camurus.com About Camurus Presentations Products Technologies Investors Career Legal notice Privacy policy Contact IR contact By continuing to use the site, you agree to the use of cookies. more information Accept The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Close